Pharmaceuticals

Gannex Announces Clinical and Preclinical Data of Four NASH Programs to be Presented in Oral or Poster Presentation at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX:1672), announces today that the latest clinical and preclinical data of four NASH programs (ASC40/TVB-2640 co-authored with Sagimet Biosciences Inc., ASC41, ASC42 and ASC43F) will...

2021-10-13 20:30 4132

One-shot Sputnik Light vaccine (first component of the Sputnik V vaccine) demonstrates 70% efficacy against infection with the Delta variant during the first three months after vaccination, Gamaleya Center analysis shows

* The vaccine is more than 75% effective among subjects under the age of 60. Sputnik Light also provides much higher efficacy against severe disease and hospitalizations.  * Sputnik Light has demonstrated a superior efficacy compared with some two-shot vaccines, which have shown a major decli...

2021-10-13 20:30 5645

Berry Oncology Releases Latest Research Results on Early Screening for Multiple Cancers

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Berry Oncology, a Chinese oncology genomic testing company, was invited to the inaugural International Biopharma Industry Week inShanghai (IBIWS) running from October 11-14, where CEO Jun Zhou delivered a much-anticipated keynote speech at the "2021 Future ...

2021-10-13 20:20 4413

I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China

* Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for second-line treatment of multiple myeloma (MM) * Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021 * New IND application for combination of felz...

2021-10-13 20:00 1884

Shanghai, industry partners to co-build world-class biopharma industry cluster

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- This is a report from China.org.cn: The 2021 International Biopharma Industry Week opened in Shanghai on Oct. 11, bringing together industry gurus, research minds, investors, and government representatives to discuss the latest trends in the biopharmaceutic...

2021-10-13 19:43 1906

The CDE Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the Center for Drug Evaluation (CDE) NMPA has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with ...

2021-10-13 15:47 1678

Accelerate Innovation Towards the Future,SAB of Winhealth Pharma Formally Established

HANGZHOU, China, Oct. 12, 2021  /PRNewswire/ -- On October 12, 2021, Hong Kong Winhealth Pharma Group, (hereinafter referred to as "Winhealth Pharma") announced the formal establishment of its Scientific Advisory Board (SAB), aiming to further expand and optimize the Group's strategic layout in m...

2021-10-12 23:45 3274

DarwinHealth Announces Scientific Collaboration with Prelude Therapeutics to Develop Novel Biomarkers for Multiple Oncology Candidates

NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing itsBiomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed ...

2021-10-12 22:52 3597

Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

* Expansion in Carlsbad, California, USA, doubles production capacity to support commercialization and industrialization of viral vectors * Investment serves customers in addressing larger patient populations with new curative treatments * Enables suspension production of viral vectors up to...

2021-10-12 21:00 4077

CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan

TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed bySingapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients inJapan, today entered into an exclusive licensing agreement with Albireo Pharm...

2021-10-12 20:30 3344

CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan

TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed bySingapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients inJapan, today entered into an exclusive licensing agreement with Albireo Pharm...

2021-10-12 20:30 1672

Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine

Agreement Expands on the Companies' Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies TORRANCE, Calif., Oct. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle ce...

2021-10-12 20:23 2930

Shanghai Pharmaceuticals and Luca Healthcare Announce a Strategic Collaboration to Provide Home Drug Delivery to Rare Disease Patients on Luca Healthcare's Patient Management Platform

SHANGHAI, Oct. 12, 2021 /PRNewswire/ -- SPH Health Commerce, the Direct-to-Patient ("DTP") retail pharmacy subsidiary of Shanghai Pharmaceuticals and Luca Healthcare,China's category leader in clinically validated, software-based screening, treatment and management tools, today announced a strat...

2021-10-12 19:21 2926

Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins

FREIBURG, Germany, Oct. 12, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produc...

2021-10-12 10:30 3337

EVERSANA™ named a Great Place to Work for third consecutive year in U.S.; earns valuable recognition in Canada, China and India

CHICAGO, Oct. 11, 2021 /PRNewswire/ -- EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, is celebrating its designation as aGreat Place to Work® by the global authority in workplace culture. Based on an anonymous survey to more than 3,000 EVERSANA...

2021-10-11 23:22 4264

Twist Alliance Pan-Cancer Methylation Panel Global Launch Event - A Strategic Collaboration Between AnchorDx and Twist Bioscience for Pan-Cancer Liquid Biopsy

GUANGZHOU, China, Oct. 11, 2021 /PRNewswire/ -- The Twist Alliance Pan-Cancer Methylation Panel (Pan-Cancer Panel), a solution for pan-cancer study including DNA methylation library preparation and targeted enrichment for next-generation sequencing (NGS), was launched globally onSeptember 24th (U...

2021-10-11 21:00 4344

Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres® Y-90 resin microspheres in China

WOBURN, Mass., Oct. 11, 2021 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that the first procedure of selective internal radiation therapy (SIRT) using SIR-Spheres®Y-90 resin microspheres in China was successfully performed ...

2021-10-11 20:00 2850

Sai Life Sciences presents mid-term report on Sai Nxt initiative; reveals upsurge in capabilities

- Completes two-thirds of its investment target of US$150M - Demonstrates a leap forward in capabilities across all focus areas – People, Processes, and Infrastructure HYDERABAD, India, Oct. 11, 2021 /PRNewswire/ -- Sai Life Sciences, a leading globalContract Research, Development and Manufac...

2021-10-11 16:50 4113

Kintor Pharma Announces China NMPA Approves Clinical Trial of ALK-1 and Nivolumab Combination Therapy for the First-line Treatment of Advanced Hepatocellular Carcinoma

SUZHOU, China, Oct. 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the clinical trial of ALK-1 antibody (GT90001C) and Nivolumab (O...

2021-10-11 13:00 6638

Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease

DURHAM, N.C. and BEIJING, Oct. 9, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health...

2021-10-09 03:07 6341
1 ... 315316317318319320321 ... 342